Research Update: Making an Impact for GBM Patients
[vc_row][vc_column][vc_single_image image="69243" img_size="full" alignment="center" css=""][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=""] Glioblastoma (GBM) is the most aggressive form of brain cancer with a uniformly fatal diagnosis, limited treatment options, and a median survival of less than two years. Although chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of certain cancers,...